Trevi (TRVI) First to Show Positive IPF Chronic Cough, RCC Data - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $25.00 price target on Trevi Therapeutics (NASDAQ: TRVI).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
